Overview

Lahive & Cockfield’s IP Litigation group represents both plaintiffs and defendants in cases involving patents, trademarks, copyrights, and trade secrets. We know that to succeed in litigation, you need lawyers who comprehend technology and also know how to win in court. Our team approach to litigation brings to bear the full range of expertise of our trial attorneys, patent lawyers, patent agents, and technical specialists, including many with advanced engineering and scientific degrees. We understand how to teach technology to judges and juries to achieve favorable results through litigation.

Services

We advise clients on a full range of intellectual property litigation, enforcement, arbitration and mediation matters including strategy and implementation. Our attorneys have many years of experience litigating complex intellectual property cases at the federal district court level as well as before the U.S. Court of Appeals for the Federal Circuit. We also understand the complex world of USPTO practice, including interferences and reexaminations.

Our attorneys are often called upon to assess the risks of patent litigation for clients that are involved in developing new technologies or engaged in due diligence. We discuss frankly with clients the costs and risks of litigation, and we encourage creative alternative resolutions when that is in the client’s interest. Lahive’s intellectual property litigation risk assessments enable clients to make informed business decisions when contemplating whether to commence litigation, how to respond to cease and desist letters, and how to defend against lawsuits that have been filed against them.

Representative Clients

We represent both large and small clients in a broad range of industries and specialty areas, including such diverse technologies as semiconductors, medical devices, high-speed liquid chromatography, telecommunications, RFID tracking systems, avionics, Section 1498 patent infringement suits against the federal government, biotechnology, drug development screening, pharmaceutical, and Hatch-Waxman Paragraph IV ANDA litigations.